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INTRODUCTION
Cancer is a leading cause of death internationally and is the second leading cause of death in Ireland after 
cardiovascular diseases, a pattern commonly seen in developed countries (WHO, 2008). Specifically, in Ireland 
cancer deaths represented 30% of all deaths in 2010 amounting to an average of over 8,000 deaths annually 
(NCRI, 2013a). The consequences of cancer-related mortality are tragic on a personal level for those affected, but 
beyond this there are also implications for public health, the economy and society in general. This study focuses 
on one aspect of cancer, namely the costs this disease impose on employees and employers from an economic 
perspective (Hanley and Sharp, 2012; Oliva et al., 2005).
When an employed individual is diagnosed with cancer, a short- or long-term absence from work normally ensues 
due to treatment, related side effects or rehabilitation (Bradley et al., 2006; Mehnert, 2011; Mehnert et al., 2013; 
Sharp and Timmons, 2011). A proportion of patients with cancer also leave the workforce permanently either due 
to retirement or death. It is the latter of these – specifically cancer-related premature mortality – that constitutes the 
focus of this study. Premature mortality results in firm turnover which, in turn, constitute direct and indirect economic 
losses to the employer. The former arise because of the need to fund such things as separation, replacement and 
training (Tziner and Birati, 1996) and the latter from lost productivity itself. Specifically, the investment that the 
employer made in the employee is lost if they leave the workforce due to cancer, and this creates a quantifiable cost.
A number of distinct models exist for calculating the costs of turnover in the workforce (Cascio, 1991; Karsan, 
2007; Tziner and Birati, 1996); however, these tend to follow general accounting approaches rather than applying 
economic costing techniques. Where economic costing techniques have been applied, the majority of studies 
have adopted the human capital approach (HCA) to productivity cost estimation, which measures potential output 
lost due to absenteeism and turnover rather than actual output loss. More recent conceptual developments have 
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Abstract:  The extant literature suggests that cancer-related premature mortality costs have increased over time and are projected to increase 
further. Previous studies have generally employed a societal rather than an employer-based costing framework. A question therefore 
remains over the magnitude of productivity costs associated with premature death from cancer from an employer perspective. The 
objective of this study was to measure the productivity costs associated with cancer-related premature mortality in Ireland using the 
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resulted in the development of the friction-cost approach (FCA), which has been claimed as a more meaningful 
measure of productivity losses from the employer’s perspective (Koopmanschap et al., 1995) because it measures 
the actual output loss following temporary absence or permanent removal of a worker up to the point where the 
initial firm output level is restored; these two approaches are described in more detail below.
The extant literature suggests that cancer-related premature mortality costs are significant, have increased over 
time and are projected to increase further (Hanly et al., 2014). For example, in Europe, all cancer sites combined 
generated a total of €75 billion in premature mortality costs in 2008 (Hanly et al., 2015). In addition, in the US, total 
cancer premature mortality costs were forecasted to increase by 27% from $116 billion in 2000 to $147 billion in 
2020 (Bradley et al., 2008). However, both these studies used the HCA. In fact, very few studies have attempted 
to estimate cancer-related productivity losses using the FCA and, of those which have been reported, none have 
estimated costs for a range of cancer sites (Hanly et al., 2014). This is an especially important gap in the literature in 
the current economic climate; it has been argued that the FCA becomes particularly applicable during periods of less 
than full employment (Koopmanschap and Rutten, 1996). Consequently, a question remains over the magnitude of 
the actual productivity costs associated with premature death from cancer from an employer’s perspective. The lack 
of FCA-based estimates of productivity costs are also important in light of the fact that economic evaluations are 
increasingly used to inform decisions on the introduction of new health technologies internationally; although many 
of the economic evaluation guidelines incorporate productivity costs (Knies et al., 2010), there is no consensus 
within these guidelines as to what costing perspective should be adopted.
We aimed to use the FCA to measure cancer-related premature mortality costs in Ireland. Our study entailed 
the application of a conceptualisation of involuntary turnover costs rarely used in the management literature (FCA) 
and represents the first estimate of productivity costs associated with cancer-related premature mortality across 
multiple sites from an employer’s perspective in Ireland. As the only study to have applied the FCA to estimate 
costs for multiple (more than two) cancer sites, it also constitutes an important contribution to the international 
evidence-base. Moreover, we incorporated recent advances in the methodology underpinning FCA – which have 
only been previously applied in the Netherlands (Krol et al., 2012) and the US (Nicholson et al., 2006) to model the 
sensitivity of our costs to ‘multiplier effects’, which arise from modern working practices. This includes accounting 
for the additional effects of turnover on team-based work, time-sensitive demand and replacement workers, and the 
incorporation of which constitute an important contribution to the management literature. Finally, we modelled the 
effect of changing labour market conditions on our estimates including rising unemployment levels in Ireland. The 
study thus purports to estimate a more complete value for the lost productivity associated with involuntary turnover 
and provide a more meaningful measure of lost productivity than traditional turnover frameworks.
INVOLUNTARY EMPLOYEE TURNOVER COSTS: FROM THEORY TO PRACTICE
Although a considerable breadth of literature exists on the issue of employee turnover, with a recent review (Steel 
and Lounsbury, 2009) counting 24 distinct turnover models in print, the majority of this concentrates on voluntary 
turnover, which is defined as the movement across the membership boundary of an organisation initiated by the 
employee (Price, 1977). Previous studies, including the seminal work by March and Simon (1958), have examined 
the employee decision to quit based on perceived ease and desirability movement. Refinements of this model 
included a base turnover model, which extended the knowledge of the withdrawal process (Mobley, 1977; Mobley 
et al., 1978, 1979), in addition to more recent turnover models informed by developments in decision theory and 
which incorporate human decision making as a non-linear process (Lee and Mitchell, 1994; Steel, 2002).
Involuntary turnover, in contrast, can be defined as the movement across the membership boundary of an 
organisation, which is not initiated by the employee (Price, 1977). It is this involuntary turnover, and in particular that 
linked to deaths (rather than dismissals and retrenchments as defined by Campion (1991)), which comprises the 
focus of the current study. Our specific focus is on ‘premature’ deaths due to disease/illness, in this instance cancer. 
‘Premature’ mortality is defined here as death that occurs prior to an individual’s retirement from paid employment, 
although it may be defined in other ways (such as deaths before average life expectancy).
Following the publication of conceptual frameworks on employee turnover (summarised above), a number of 
studies attempted to examine the financial effects of turnover from the employer’s perspective (Cascio, 1991; 
Karsan, 2007; Tziner and Birati, 1996). These works traditionally involve the use of general accounting approaches 
to produce an estimate of the costs of turnover to the employer. These estimates may incorporate a range of potential 
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direct costs comprising separation costs, including the costs of an exit interview, administration of employee removal 
and severance pay; replacement costs including advertising a position, processing applications, interviews and 
orientation activities; and training costs, including disseminating organisational information on regulation, conduct, 
performance and socialisation, in addition to formal training programmes (Cascio, 1991).
Although there are clearly many forms of direct costs, the indirect costs associated with employee turnover 
(such as the lost production to the firm following the premature death of the employee) can dwarf these costs. 
Indirect costs, it may be argued, are more aptly captured through the use of economic costing techniques (although 
some interesting attempts to quantify these have been made using more traditional accounting practices (Cascio, 
1991; Tziner and Birati, 1996)). The economic costing approach attempts to go beyond the traditional financial cost 
of turnover in measuring the indirect costs of turnover for employers, and (depending on the methodology adopted) 
for the economy, or society, in general.
In economic costing studies, measurement of disease-related indirect costs was originally undertaken according 
to the HCA. The HCA adopts a societal, or welfare-based, perspective and attempts to measure the potential stream 
of output that could have been produced over the course of a lifetime without premature death (in this case, due 
to cancer). This method values productivity loss as the present value of foregone future income, with lost income 
acting as a proxy for lost output (Berger et al., 2001; Tarricone, 2006). In a number of seminal studies, Rice (1966, 
1967) calculated disease-related morbidity and mortality costs by assessing illness burden in terms of the flow 
of goods and services foregone in the US. Further development of this conceptual approach was undertaken by 
Mushkin (1962) who used the HCA in the health care field to evaluate the potential for economic growth. However, 
some authors (Drummond, 1992; Koopmanschap et al., 1995) have argued that the actual productivity loss in an 
economy is much smaller than this when a reserve pool of labour – i.e. unemployed people - exists.
A major conceptual development was initiated in the 1990s with the introduction of the friction-cost approach 
to productivity cost estimation (Koopmanschap et al., 1995). This alternative employer-based perspective values 
productivity loss over the time span that firms require to restore the initial production level following the loss of 
a worker (Koopmanschap et al., 1995) and can measure the costs of both temporary work absences and more 
permanent absences such as those due to premature mortality. It is assumed that, following a premature death of 
a worker, she/he is replaced by an unemployed individual, either directly or at the end of a chain of vacancies; this 
replacement incurs zero opportunity cost. The time period necessary to re-establish the original production level is 
referred to as the ‘friction period’ and can vary depending on extant labour market conditions. Generally, the higher 
the level of unemployment in an economy, the shorter the friction period because more potential workers with 
the requisite skill set are available to replace workers lost due to premature death. Unlike the HCA, the FCA also 
incorporates the cost for hiring and training new workers, although this is measured in an indirect manner through 
time costs; additional direct costs are not captured.
Some authors argue that the wage rate represents a lower bound for productivity costs in that it does not take 
into account: (i) the team-dependent nature of the modern work environment which means that the loss of one team 
member may inhibit the productivity of the entire team; (ii) the difficulty in finding a perfect substitute replacement 
worker which may entail comprehensive training until the appointee is as productive as the lost worker and (iii) the 
fact that a proportion of current firm-level demand is highly time sensitive and the loss of a worker may inhibit the 
timely supply of the necessary goods or services (Nicholson et al., 2006; Pauly et al., 2002). These arguments have 
been echoed in the managerial literature which also notes the additional effects of turnover on morale and the cost 
of maintaining a ‘bench’ – a group of people available to cover the work of a terminated employee until the new hire 
is fully ready (Curtis and Wright, 2001; Karsan, 2007; Tziner and Birati, 1996). More recent discussion has focused 
on the consequences of grief in the workplace following the loss of a colleague, and the productivity costs associated 
with this (Hazen, 2008, 2009; James and Friedman, 2003). In particular, these additional costs would include the 
potential impact on colleagues’ productivity due to the loss, through a cancer death, of an individual in the workgroup. 
These costs could be in excess of the pure productivity loss arising from the loss of a team member and relate to the 
additional effects of grief in the workplace. Recent conceptual developments in the FCA have involved adjustment of 
the wage rate for a limited number of such so-called multiplier effects (Nicholson et al., 2006; Pauly et al., 2002), but 
few studies have so far investigated the impact on productivity costs of incorporating these effects.
In light of these conceptual and methodological advances in productivity cost estimation from an economic 
perspective in recent years, it is now apt to apply the most up–to–date conceptualisation of productivity costs to cancer 
in Ireland. Given the dependence of the FCA on underlying economic conditions (Koopmanschap and Rutten, 1996), 
Ireland provides an interesting case study for the application of the methodology. For example, unemployment – which 
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is a key driver of the friction period – increased from 4.7% in 2007 to 13.1% in 2013 (Statbank, 2014a). In this study, 
we model the effects of these increased unemployment levels on productivity costs while also being the first to apply 
the ‘multiplier effects’ to Ireland. In the discussion, we compare the FCA with other economic and financial costing 
frameworks to explore a key weakness in the current conceptualisation of the FCA from a management perspective 
and possible future enhancements to the approach. Finally, we consider what the results mean for the debate on the 
appropriate perspective and therefore costing approach to employ within economic evaluations.
METHODS
Our study addresses four research questions: (1) what is the magnitude of productivity costs associated with 
cancer-related premature mortality in Ireland in 2009 (the base-case year) according to the FCA; (2) to what extent 
do changing labour market dynamics and the multiplier effects of job turnover impact on FCA productivity cost 
estimates; (3) how does the FCA productivity cost compare to other economic and financial estimates of premature 
mortality and (4) what conceptual and methodological refinements are required in the FCA, if any, to provide a 
meaningful managerial assessment of turnover costs due to premature death.
The conceptual framework underpinning the FCA comprises four core components which aggregate together to 
produce productivity cost estimate. The first component is the length of the friction period. The second component is the 
time lost from work due to illness, which is straight forward in the case of premature mortality. In this study, premature 
mortality is defined as deaths due to cancer which occurred before 65. Conceptually, the FCA can incorporate any type 
of workforce absence including temporary and permanent disability; but absences other than those due to premature 
death are beyond the scope of the current study. The third component is an estimate of the wage rate, which acts 
as a proxy for lost productivity and is used to cost the time estimates. Finally, the fourth component is an estimate 
of proportion of reduction in effective labour time resulting from a work absence which might be <1 because of, 
for example, a firm’s internal labour reserves (Hanly et al., 2012). A fifth – optional – component is an estimate for 
‘multiplier effects’, which are considered through sensitivity analyses in the current study.
Data sources
Cancer data: We abstracted data on the average annual number of cancer deaths between the ages of 15 and 
64 in Ireland during 2005–2009 by 5-year age group and sex from the World Health Organization (WHO) Cancer 
Mortality Database (WHO, 2013). We considered all cancers combined (International Classification of Diseases 
(ICD 10 00-97, B21)) and the 10 cancer sites in males and females for which there were most deaths in people of 
all ages. These were oesophagus (ICD10 15, males and females); stomach (C16, males and females); colorectal 
(C18-21, males and females); pancreas (C25, males and females); lung (C33-34, males and females); breast (C50, 
females); uterus (C53-55, females); ovary (C56, females); prostate (C61, males); bladder (C67, males); brain and 
central nervous system (CNS, C70-72, males and females); non-Hodgkin’s lymphoma (C82-85, C96, males and 
females) and leukaemia (C91-95, males and females).
Labour market data: We extracted job vacancy duration data from a Central Statistics Office (CSO) survey of 
‘Employee Skills, Training and Job Vacancies’ (CSO, 2009). From this, we derived a friction period of 11.3 weeks, 
composed of the average job vacancy duration in 2006 (7.3 weeks – the closest year to the base year for which 
an estimate was available – plus an additional 4 weeks to account for the time required to advertise a job, recruit a 
replacement worker and provide initial training (Hanly et al., 2012; Tan et al., 2012)). After this period, a firm’s initial 
production level is assumed to be restored. This estimate was used in the base-case analysis. Other base-case 
valuation data included age- and gender-specific gross annual wages (including bonuses and benefits-in-kind), which 
came from the National Employment Survey 2009 (Statbank, 2014b), and age- and sex-specific unemployment and 
labour force participation rates, which were derived from the Quarterly National Household Survey (Statbank, 2014a). 
Wages were used as a proxy for output loss, as assumed elsewhere in the literature (Tarricone, 2006).
Estimation methods
In order to estimate the cost of cancer-related premature mortality for Ireland, we first calculated the annual years 
of potential productive life lost (YPPLL) due to cancer between the ages of 15 (before which it is assumed that 
workforce participation is negligible) and 64. The upper threshold was based on the pensionable age in Ireland in 
2009 and is close to effective male and female retirement ages (64.6 for males and 62.6 for females) between 2009 
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and 2012 (OECD, 2013). YPPLL were capped at the base-case friction period of 11.3 weeks, and we then valued 
these capped YPPLL. In practice, this involved multiplying the friction period (expressed as a fraction of a working 
year, which was assumed to be 48 weeks) for an individual death by age- and gender-specific annual wages. For 
example, a female who died from breast cancer between the ages of 45 and 49 had an assumed annual wage of 
€37,140 which was multiplied by 11.3/48 (0.2354). We then adjusted for population-level gender-specific labour 
force participation and unemployment rates. Estimates were subsequently summed over deaths in each 5-year age 
group to yield age group totals and across age groups to provide totals for all ages. This was done for all cancers 
combined and each cancer site. Productivity costs were also expressed per cancer death based on the number 
of deaths in the 15–64 age group. For example, there was an estimated 134.6 (average during 2005–2009) male 
deaths between 15 and 64 from colorectal cancer with an estimated total cost of €1,182,056. The cost per cancer 
death was €1,182,056/134.6 or €8,782. All costs were expressed in 2009 euros.
Sensitivity analyses
Three sensitivity analyses were conducted. First, we accounted for ‘multiplier effects’ (Nicholson et al., 2006; Pauly 
et al., 2002) by applying the median multiplier estimate of 1.28, derived by Nicholson et al. (2006), to our base-
case estimates for all cancers combined in males and females. Next, we explored the impact on the all cancers 
premature mortality cost of the change in unemployment levels between quarter 3 2006 (when the vacancy period 
was estimated in the base-case) and 2013 (Statbank, 2014a). Firstly, using adjustment factors derived by Erdogan-
Ciftci and Koopmanschap (2011), we calculated a revised friction period for 2009 of 7.2 weeks and applied this. 
Secondly, we repeated the analysis using the base-case friction period of 11.3 weeks and 2013 unemployment and 
labour force participation rates.
RESULTS
Total deaths by cancer site and gender
The annual number of cancer deaths in people of all ages in Ireland was 8,067, with males accounting for 53% of 
this total (Table 1). The top 10 most common sites in terms of deaths accounted for 76.5% and 75.4% of all cancer 
deaths for males and females, respectively. Lung cancer was the most common cause of death in males (994 
deaths per annum; 23% of the total), followed by colorectal cancer (554 deaths; 13%). Breast cancer was the most 
common cause of cancer-related death in females (679; 18%) followed closely by lung cancer (668; 18%) with 
colorectal cancer a more distant third (401; 11%).
Total cancer-related premature mortality costs by site and by gender
In the base-case, total productivity costs due to cancer-related premature mortality amounted to €14.3 million, 70% 
of which was accounted for by premature mortality in males (Table 1). Combining males and females (Figure 1), 
lung cancer was the most expensive site generating €3.1 million in productivity costs (22% of the total). This was 
followed by colorectal cancer (€1.5 million; 11%) and female breast cancer (1.2 million; 8%). In combination, these 
three cancers accounted for over 40% of the total cancer-related premature mortality costs.
Male total productivity costs due to premature mortality for all cancer combined were 2.3 times greater than 
female costs (€10.0 million vs. €4.4 million). The most expensive cancer site in males was lung (total cost €2.5 
million), followed by colorectal cancer (€1.2 million) and cancers of the brain and CNS (€0.7 million). Breast cancer 
generated the highest total premature mortality cost for females (€1.2 million), followed by lung cancer (0.7 million) 
and cancer of the uterus (0.4 million).
Total cancer-related premature mortality costs by age
All cancer total productivity costs due to premature cancer-related mortality increased with increasing age for both 
males and females (Figure 2), peaking in the 55–59 age group and falling slightly in those aged 60–64. Male and 
female productivity costs were similar to age 39; thereafter male costs substantially exceeded female costs in all 
age groups. The difference in costs between the sexes was highest in the 60–64 age group, where male costs were 
3.5 times higher than female costs.
9
Brought to you by | Newcastle University
Authenticated
Download Date | 7/13/17 4:03 PM
Cancer and productivity loss in the Irish economy:
Table 1. Average annual number of deaths (all ages, 2005–2009), total productivity costs due to premature mortality and premature mortality cost 
per cancer death (€, 2009) for all cancers and the 10 most common cancer sites in males and females in Ireland
Cancer site Deaths  (% of the total) Rank
Total premature mortality 






All cancers 8,067 14,328,884 6,339
Males
All cancers 4,276 (100) - 9,971,386 (100) - 8,709 -
Top 10 cancers 3,272 (76.5) - 7,229,907 (72.5) - 8,776 -
 Oesophagus 218 (5.1) 4 613,083 (6.1) 5 8,860 4
Stomach 207 (4.8) 6 488,815 (4.9) 6 8,920 2
Colorectal 554 (13.0) 2 1,182,056 (11.9) 2 8,782 6
Pancreas 217 (5.1) 5 623,921 (6.3) 4 8,837 5
Lung 994 (23.4) 1 2,475,876 (24.8) 1 8,693 8
Prostate 530 (12.4) 3 327,945 (3.3) 8 8,496 10
Bladder 121 (2.8) 10 164,105 (1.6) 10 8,729 7
Brain and CNSa 150 (3.5) 8 675,722 (6.8) 3 8,891 3
Non-Hodgkin’s 
lymphoma 132 (3.1) 9 382,405 (3.8) 7 9,148 1
Leukaemia 150 (3.5) 7 295,980 (3.0) 9 8,554 9
Females
All cancers 3,791 (100) 4,357,498 (100) - 3,932 -
Top 10 cancers 2,860 (75.4) 3,550,112 (81.5) 3,941 -
Oesophagus 118 (3.1) 8 75,983 (1.7) 10 3,689 8
Stomach 130 (3.4) 7 114,936 (2.6) 8 4,105 3
Colorectal 401 (10.6) 3 324,131 (7.4) 5 3,850 5
Pancreas 218 (5.8) 5 162,928 (3.7) 7 3,542 10
Lung 668 (17.6) 2 668,696 (15.3) 2 3,642 9
Breast 679 (17.9) 1 1,194,773 (27.4) 1 4,169 2
Uterus 172 (4.5) 6 359,976 (8.3) 3 4,337 1
Ovary 254 (6.7) 4 345,602 (7.9) 4 3,798 7
Brain and CNS 109 (2.9) 10 201,984 (4.6) 6 3,945 4
Non-Hodgkin’s 
lymphoma 111 (2.9) 9 101,102 (2.3) 9 3,801 6
aCentral nervous system
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Figure 1 Percentage and value of total productivity costs due to premature mortality (€, 2009), by cancer site, for males and females 
combined 
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Figure 1. Percentage and value of total productivity costs due to premature mortality (€, 2009), by cancer site, for males and females combined
Figure 2. Total productivity costs due to premature mortality (€, 2009), all cancers combined, by sex and age Figure 2 Total productivity costs due to pre ature mortality (€, 2009), all cancers combined, by sex and age 
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Cancer-related premature mortality cost per death by site and by gender
When expressed per cancer death, all cancer premature mortality costs in males were more than double those 
in females (€8,709 per death vs. €3,932 per death). This pattern was also seen for all sites for which costs were 
computed for both sexes. The highest premature mortality cost among males was for non-Hodgkin’s lymphoma 
(€9,148 per death), and the lowest was for prostate (€8,496 per death); for females the highest cost per death was 
seen for cancer of the uterus (€4,337 per death) and the lowest for cancer of the pancreas (€3,542 per death).
The ranking of cancers changed considerably when cost per death was considered rather than total productivity 
costs due to premature mortality. For example, while lung cancer was the most costly cancer site in males in terms 
of total costs, it ranked 8th according to productivity cost per death. For females, while cancer of the uterus ranked 
third according to total productivity cost, it was the most costly site according to productivity cost per death.
Sensitivity analyses
The results of the sensitivity analyses are presented in Figure 3. Accounting for the existence of job-dependent 
multiplier effects resulted in an increase in all cancer total productivity costs due to premature cancer-related 
mortality compared to the base-case estimates of 16.7% in males and 29.1% in females. Conversely, decreasing 
the friction period from 11.3 weeks to 7.2 weeks resulted in falls of 41.9% and 35.8% in all cancer productivity costs 
in males and females, respectively, compared to the base-case figures. Finally, the use of 2013 unemployment and 
participation rates had a modest impact on the all cancer costs in males (−8.8%) and almost no impact in females 
(+0.8%).
Figure 3. Sensitivity analysis: total productivity costs due to premature cancer-related mortality (€, 2009) according to different assumptions for 
the labour market (unemployment rates, participation rates and wage rate multipliers), all cancers combined, by sex
 
Figure 3 Sensitivity analysis:  total productivity costs due to premature cancer-related mortality (€, 2009) according to differe t 
assumptions for the labour market (unemployment rates, participation rates and wage rate multipliers), all cancers combined, by sex 











































Adjusted friction period (for 2009 labour market data)b 
Adjusted for 2013 labour market data onlyc
a Median l iplier estimate of 1.28 applied to base-case e timates
b Revised friction period for 2009 of 7.2 weeks applied to base-case estimates
c Base-case friction period of 11.3 weeks and 2013 unemployment and labour force participation rates applied to base-case estimates
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DISCUSSION
An employer’s perspective on the cost of cancer-related premature mortality
Cancer, and indeed any serious illness, can degrade the quality and reduce the quantity of labour available, and 
this can have both broad macroeconomic implications in terms of reduced GDP growth (Bloom et al., 2011; Mayer-
Foulkes, 2011; Swift, 2011) and firm-level effects including, among other things, productivity loss (Hanly et al., 2012; 
Nicholson et al., 2006; Oliva et al., 2005). Employers are becoming increasingly aware of adverse illness-related 
effects which may include a loss of critical skills obtained through years of on-the-job experience, higher employee 
turnover, and the need to promote employees prematurely to replace more experienced workers (Berger et al., 
2001; Bloom et al., 2011; Hytter, 2007).
In this study, we used the FCA conceptual framework to estimate the magnitude of productivity costs incurred 
due to cancer-related premature mortality. From an employer’s perspective, the FCA might be considered to provide 
a more realistic valuation of productivity costs pertaining to firm mortality-related turnover than the rival economic 
costing framework, the HCA, and thus be more informative for managerial decision making. The total all cancer 
premature mortality cost in Ireland in 2009 was estimated at €14.3 million. A previous study of Irish cancer-related 
premature mortality costs using similar data sources but applying the HCA estimated a total productivity cost of 
€509.5 million for 2009 (Hanly and Sharp, 2014). Controversy remains around the correct economic method for 
measuring and valuing productivity costs (Knies et al., 2010; Krol et al., 2013). In the relatively few available 
studies, it has consistently been shown that the FCA results in losses, which are substantially lower than those 
generated using the HCA (Goeree et al., 1999; Hanly et al., 2012; Hutubessy et al., 1999). For example, in studies 
in Ireland and Spain which considered specific cancers, FCA estimates for cancer-related productivity losses were 
approximately 1.2%–2% of HCA estimates (Hanly et al., 2012; Oliva et al., 2005); the comparison of the all cancer 
figure derived in the current study with the all cancer HCA estimate previously reported (Hanly and Sharp, 2014) 
is broadly consistent with these ratios. The difference arises as the HCA measures potential output loss while the 
FCA measures actual output lost, which means that the HCA losses accrue over a lifetime (or, at least until the 
usual retirement age) while those for the FCA are truncated at the end of the friction period when output is assumed 
restored.
The traditional employee turnover cost literature which applies accounting costing procedures decomposes 
the cost of turnover into three direct cost components: separation costs, replacement costs and training costs, and 
an indirect component of reduced productivity (Cascio, 1991; Pinkovitz et al., 1997; Tziner and Birati, 1996). The 
indirect component tends to concentrate on the cost of the reduced productivity of the new worker until they have 
reached the level of the previous employee, rather than the lost productivity cost over the entire ‘friction period’ 
(Cascio, 1991). Consequently, this represents a partial measure of productivity loss. The FCA purports to capture 
a more comprehensive measure of the lost productivity component and therefore provides a more meaningful 
measure of lost productivity compared to traditional turnover frameworks. Nevertheless, the FCA only measures 
one of the three direct costs outlined in the traditional accounting framework, and even then only indirectly. For 
example, the FCA estimates training costs as the time, and therefore lost productivity, necessary for the new hire to 
restore the original output level. It fails to incorporate the direct costs of training which can include those associated 
with the dissemination of firm information on organisational regulations, norms of conduct and core organisational 
values, in addition to setting up training programs and on-the-job training activities. Separation and replacement 
costs are similarly overlooked. This lack of recognition of direct costs associated with turnover remains a weakness 
of the FCA, if it claims to truly represent an employer’s perspective.
Additional turnover costing approaches in the literature have highlighted the importance of other potential 
consequences, which may result from involuntary employee turnover, such as a fall in morale of remaining staff 
(and associated lost productivity), customer loss due to failure to supply services or products on schedule and the 
cost of maintaining a ‘bench’ (Curtis and Wright, 2001; Karsan, 2007; Tziner and Birati, 1996). These consequences 
can lead to further costs from an employer’s perspective. Although they have not all been incorporated within the 
FCA, consideration of these types of issues led to the development of the concept of ‘multiplier effects’ (Krol et al., 
2012; Nicholson et al., 2006; Pauly et al., 2002).
Multiplier effects incorporate the additional effects of turnover on team-based work, time-sensitive demand and 
where perfect substitute workers are hard to find. Sectors where vacancies are ‘difficult-to-fill’ in Ireland include ICT, 
high-tech manufacturing, agri-food, financial services and healthcare (FAS, 2013) and therefore we would expect 
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the actual productivity losses in these sectors during the friction period to be higher than average. In our sensitivity 
analysis we applied a multiplier (1.28) derived from US-based firms (Nicholson et al., 2006) to account for these 
additional turnover costs. This increased Irish cancer-related premature mortality costs by 17% (to €11.6 million) 
for males and by 29% (to €5.6 million) for females. We suggest that these figures are perhaps more indicative of 
the true indirect employer costs associated with cancer-related premature mortality, but advise some caution in 
interpretation because of the source (i.e. US) of the multiplier estimate; an estimate for Ireland is not (as far as we 
are aware) available.
Productivity cost estimation in practice: variation in premature mortality productivity costs by 
sex and age
We found that the all cancer total premature mortality cost for males in Ireland was 2.3 times higher than that 
for females and a similar difference was observed in the cost per cancer death. This was despite the fact that 
average number of deaths from cancer in people aged 15–64 was similar in males and females (1,145 and 1,108, 
respectively). This pattern is consistent with findings from the studies of premature cancer-related mortality costs 
using both the FCA and the HCA conducted in other countries (Hanly et al., 2014).
The higher premature mortality cost for males than females is largely a result of gender differences in labour 
market factors, which are incorporated in the calculations, including wages and workforce participation rates; both 
of these are substantially higher in males than females. For example, among workers in Ireland aged 40–49, the 
average male wage was €55,800 per annum compared to €37,140 for females (Statbank, 2014b). This wage gap 
is a function of many factors, including the higher average number of hours worked per week by men than women 
(39.4 vs. 30.6), men’s greater average years of work experience and the fact that more men than women have 
supervisory positions (CSO, 2011; ESRI, 2003). In addition, in the 45–49 age group, for example, 88% of males 
participated in the workforce compared to 68% of females (Statbank, 2014a).
We also observed a trend of rising total all cancer premature mortality costs with increasing age, at least 
until age 60. This is due to the fact that average wages rise with age until 60 (Statbank, 2014b) and because 
the number of deaths increases with age for most cancers. This age-specific pattern has also been observed 
in studies in other countries (Hanly et al., 2015), but what was particularly striking in this study was the fact 
that the male:female ratio increased substantially with age. Again this reflects male–female differentials in 
workforce participation and wages rates, which tend to increase with age. For example, while the average male 
wage in the 25–29 age group in 2009 was 12% higher than the average female wage, it is 63% higher in the 
50–59 age group.
From an employer’s perspective, the implication of these higher costs in males is that the productivity costs 
associated with the losses of male employees due to cancer-related premature mortality exceed those for 
female employees. This clearly has implications in terms of equity, and these need to be borne in mind when 
developing policies (either at the individual employer or the society level) to maximise workforce participation 
among people with cancer. The equity implications of using economic approaches to estimate productivity 
costs have been previously discussed by Williams (1992) and more recently by Krol et al. (2013).
Modelling employer productivity costs during a recession
The FCA and the related concept of the ‘friction period’ are closely linked to the extant labour market conditions in 
the economy (Koopmanschap et al., 1995). Specifically, an inverse relationship exists between the vacancy period 
of a job and the unemployment rate: the higher the unemployment level, the shorter the vacancy period, and thus 
the friction period. In sensitivity analyses, we attempted to model the effect of large increases in unemployment 
levels in Ireland over time on premature mortality costs. Interestingly, the greatest impact on costs was due to 
the change in the length of time for a firm to replace a worker, that is, the friction period; using a 7.2-week friction 
period instead of 11.3 weeks due to a 8.1% rise in unemployment from 2006 (base-case friction period year) to 
2009 resulted in 42% lower all-cancer costs for males and 36% lower costs for females. The impact of changes in 
participation and unemployment rates on costs (with the friction period held constant) was minimal. The implication 
of this is that productivity cost estimates should be updated as economic conditions change over time, especially 
if the friction period is considered to have changed. This is rarely undertaken using accounting-based frameworks 
and represents a distinct strength of the FCA framework.
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Different perspectives on the cancer burden
The traditional measures of the cancer burden (or, indeed any other non-infectious disease) – namely numbers and 
rates of new cases and deaths in a specific country or defined population – take an entirely public health view. However, 
cancer (or any other disease) also has an economic impact which can be quantified according to the perspective of 
the individuals (or families) affected, society, or – as illustrated in this study – employers. In recognition of these 
distinct economic implications of cancer, in 2009, the Commission of the European Communities (2009) called for 
comprehensive and standardised information on the costs of cancer (as well as other measures of the cancer burden) 
to facilitate benchmarking and priority setting in relation to cancer control activities. As we have noted elsewhere 
(Hanly et al., 2014), the currently available literature on premature cancer-related mortality costs has significant gaps 
and limitations; this is particularly true with regard to costs from the employer’s perspective. Studies such as this one 
are therefore important in expanding the scope of the evidence base on the costs of cancer.
The availability of both public health and economic measures of the cancer burden enables comparison between 
these different, yet complementary, perspectives and offers some interesting findings. For example, cancer of the 
prostate is the most commonly diagnosed cancer in men in Ireland and the third most common form of cancer-
related death (NCRI, 2013c). The average age at diagnosis is relatively old (68 years, NCRI, 2013a) and prognosis 
is good (5-year survival relative to the general population, 86%, NCRI, 2013c). This means that only 40% of prostate 
cancer deaths occur in men aged under 65 (NCRI, 2013b). Consequently, prostate cancer ranked only 8th in terms 
of premature mortality costs in this study, considerably lower than when viewed from a public health perspective. In 
contrast, cancers of the brain and CNS rank somewhat higher when premature mortality costs, rather than mortality 
or incidence, are considered. This cancer ranked 3rd in males and 6th in females in terms of total costs, but 8th and 
9th in terms of deaths and 13th (for males and females separately) in terms of new cases (NCRI, 2013a). This is 
primarily a consequence of the relatively low age at onset (mean = 60) and poor survival (5-year relative survival 
less than 20%; NCRI, 2013a).
Economic evaluation guidelines and productivity costs
Undertaking an economic evaluation of any health technology requires setting a perspective from which costs 
(and benefits) are measured. Traditionally national pharmacoeconomic guidelines have stipulated a health-payer 
perspective which entails the inclusion solely of direct costs that are incurred by the health provider, but there has 
been a move away from this in recent years (Knies et al., 2010). It has been argued that alternate perspectives – 
including those of the employer and society – are particularly important when the results of evaluations are aimed 
at informing resource allocation decisions (Jonsson, 2009). Importantly, in terms of this study, adopting a societal or 
employer perspective generally involves the inclusion of productivity costs, commonly defined as ‘costs associated 
with working time lost and replacement costs due to illness, disability and death of productive persons, both paid 
and unpaid’ (Brouwer et al., 1997).
Currently, almost three quarters of national pharmacoeconomic guidelines from Europe and North America 
advocate the use of a societal and/or employer perspective (Knies et al., 2010). In Ireland, the recently updated 
national guidelines for the economic evaluation of health technologies recommend the adoption of the publicly funded 
health and social care system in Ireland (i.e. the Health Service Executive (HSE)) as the reference case perspective 
(Health Information and Quality Authority HIQA, 2014). While the guidelines further note that, if the inclusion of wider 
societal costs is expected to affect the results of the evaluation significantly, then a societal perspective analysis 
should be undertaken, they recommend that this should be presented as a supplementary analysis, separate from 
the reference case (HIQA, 2014). This potentially leaves Ireland at a disadvantage internationally as inconsistency 
in the implementation of economic evaluations makes transferability of results across jurisdictions difficult (Knies 
et al., 2010). Results such as those presented here highlight the importance of economic costs over and above 
those related solely to the health system and emphasise that additional sections of society, such as employers, are 
also affected by illness.
LIMITATIONS AND FUTURE RESEARCH
From a conceptual viewpoint, the FCA provides a valuable framework for the measurement of the indirect costs of 
premature mortality-related turnover from an employer perspective. However, in its current state, this framework 
lacks a comprehensive measure of direct turnover costs. Further research in this area could concentrate on 
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combining elements of direct turnover cost (perhaps estimated according to accounting costing frameworks) with 
the indirect costs measured by the economic costing framework of the FCA. In so doing, additional costs would be 
recognised and quantified including effects on staff morale of turnover due to premature mortality and the effects 
of grief on staff. Grief, in particular, has to date remained a hidden cost but the financial and productivity effects 
are potentially large (Hazen, 2008, 2009; James and Friedman, 2003). These costs can accrue due to difficulty in 
concentration and errors in judgment, injuries and accidents (James and Friedman, 2003). Apportioning a monetary 
value to these effects would enhance measures purporting to value productivity costs.
Productivity costs related to illness can arise due to a number of distinct time losses of which premature mortality 
is only one. For example, although cancer treatment often results in full recovery, some survivors experience on-
going side effects which can impact on their cognitive and physical functioning at work (Grunfeld et al., 2008; 
Spelten et al., 2002), and hence productivity. Additional productivity costs can include temporary and permanent 
absenteeism, and return to work with reduced hours and/or reduced productivity in the workplace (presenteeism) 
(Zhang et al., 2011). Relatively, little attention has been paid to these types of cancer-related costs, particularly from 
an employer perspective. This suggests that further research might concentrate on estimating a broader range 
of cancer productivity costs. The limited extant literature has estimated that temporary and non-mortality-related 
permanent work absences can account for a considerable proportion of the total productivity costs associated with 
colorectal, prostate and breast cancer (Hanly et al., 2012, 2013), but the absolute and relative magnitude of the 
costs vary by cancer type. Therefore, further research is required to measure these additional costs across a range 
of cancer sites, particularly given improving cancer survival rates and rising retirement ages which mean that the 
number of working-age cancer survivors will continue to rise.
The application of the FCA enabled the valuation of costs from an employer’s perspective. However, this 
approach requires an estimate of the ‘friction period’ which we derived, in the base-case, from a CSO (2009) 
survey undertaken in 2006. This survey was a one-off piece of research, and, as our results demonstrate, the FCA 
estimates are rather sensitive to the assumed length of the friction period. Although we estimated changes in this 
friction period due to rising unemployment using results published in the literature, the collection of stock and flow 
data on new vacancies in the labour market would greatly enhance this process for future studies of cancer and 
other conditions.
As noted earlier, our estimate of the multiplier was obtained from a US study (Krol et al., 2012); and is, to our 
knowledge, the only available estimate. Different settings, with distinctive labour market characteristics, are likely to 
require different multiplier effects. Future research could (like the US study) undertake a survey of firms in Ireland to 
establish multipliers specific to this economy. In addition, we used a median multiplier, that is, one averaged across 
a range of professions. The application of profession-specific multipliers (which are available in the US study) is 
likely to lead to more accurate productivity cost estimates; however, Irish wage data are not reported in sufficient 
detail to enable such calculations. Thus, more detailed reporting of wage data would enhance future studies (using 
either the FCA or HCA).
Employers, supervisors and line managers play a crucial role in supporting the successful transition by cancer 
survivors back into the work environment and their subsequent retention in the workforce (Amir et al., 2008; de 
Boer, 2014). Various specific employer-related interventions – such as employer-organised return-to-work meetings, 
flexible working conditions, counselling and job replacement services – have been proposed to support this 
transition (Mehnert et al., 2013) and various vocational rehabilitation programmes have been introduced in the UK 
and elsewhere. However, these strategies have not yet been widely implemented and their effectiveness in terms 
of increasing return to work, and/or a return to full productivity at work – and, importantly, their cost-effectiveness – 
remain poorly understood. Further research is required (including in an Irish setting) on the role that employers can 
play in promoting successful return to work and ongoing retention in the workforce.
CONCLUSION
Employers are becoming increasingly aware of the adverse effects of illness on workplace productivity. Cancer, 
and specifically cancer-related mortality, imposes considerable economic costs on the employer in addition to the 
obvious huge personal loss to family and friends. Our study aimed to measure cancer-related premature mortality 
costs in Ireland using a methodological framework rarely applied in the management literature. The estimated 
results provide a sense of the types and magnitude of indirect costs which are currently excluded from existing 
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accounting methods of estimating the lost productivity of involuntary turnover. Specifically, the all-cancer premature 
mortality cost for Ireland was valued at €14.3 million in 2009 from an employer’s perspective. This estimate 
is derived from the application of a conceptualisation of involuntary turnover costs which concentrates on the 
indirect costs of involuntary turnover rather than the direct costs such as setting up training programs and on-the-
job training activities. The estimate also accounts for ‘multiplier effects’ which incorporate the additional effects 
of turnover on team-based work, time-sensitive demand and difficulty in finding perfect substitutes and therefore 
captures additional costs compared to most previous applications of the FCA. Nevertheless, the methodological 
framework applied is incomplete and future research should attempt to combine elements of direct turnover cost 
according to accounting costing frameworks with the indirect costs measured by the FCA to derive a holistic 
measure of productivity costs associated with an illness like cancer. This should entail, among other things, the 
recognition and quantification of productivity costs due to the effects of grief on workplace morale.
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